Evidence map›Paper›PMID 40065423›Full record

ArticleHarm reduction journal2025

Is fentanyl in everything? Examining the unexpected occurrence of illicit opioids in British Columbia's drug supply.

Bruce Wallace, Irene Shkolnikov, Collin Kielty, Derek Robinson, Lea Gozdzialski, Joshua Jai, Ava Margolese, Pablo Gonzalez-Nieto, Armin Saatchi, Lucas Abruzzi and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Harm reduction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Bruce WallaceSchool of Social Work, University of Victoria, Victoria, Canada. barclay@uvic.ca.
Irene ShkolnikovCanadian Institute for Substance Use Research, Victoria, Canada.
Collin KieltyCanadian Institute for Substance Use Research, Victoria, Canada.
Derek RobinsonCanadian Institute for Substance Use Research, Victoria, Canada.
Lea GozdzialskiCanadian Institute for Substance Use Research, Victoria, Canada.
Joshua JaiCanadian Institute for Substance Use Research, Victoria, Canada.
Ava MargoleseCanadian Institute for Substance Use Research, Victoria, Canada.
Pablo Gonzalez-NietoCanadian Institute for Substance Use Research, Victoria, Canada.
Armin SaatchiVancouver Island University, Nanaimo, Canada.
Lucas AbruzziDepartment of Chemistry, University of Victoria, Victoria, Canada.
Taelor ZarkovicDepartment of Chemistry, University of Victoria, Victoria, Canada.
Chris GillCanadian Institute for Substance Use Research, Victoria, Canada.
Dennis HoreCanadian Institute for Substance Use Research, Victoria, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIllicit opioids, including fentanyl, are linked to unprecedented levels of overdose in Canada and elsewhere. The risks associated with illicit opioids can include high potency, unpredictable concentration and the unexpected presence in other drugs. Within this context, we examine drug checking data to better understand the presence of illicit opioids such as fentanyl in other drugs and possible ways to interpret these results.

methodsThree years (2021-2023) of data (18,474 samples) from Substance Drug Checking in British Columbia, Canada were examined to investigate the risks associated with the detection of opioids in other drugs such as cocaine and methamphetamine, as well as in other drug categories. Samples were tested by paper spray mass spectrometry (PS-MS), fentanyl test strips and Fourier-Transform infrared spectroscopy (FTIR). We examine the 8889 samples not expected to include fentanyl to confirm; if the expected drug was detected, if unexpected opioids were detected, and when the unexpected opioids are in trace concentration.

resultsUnexpected opioids were rarely detected (2%) in other drugs (189 of 8889 samples) with most (61.4%) detected at trace concentration levels. Unexpected opioids are far more likely to be found in samples that did not contain the expected drug than in samples that were confirmed to contain the expected drug. The least common scenario (below 1%) were substances that included the expected drug plus unexpected opioid above trace concentration. These findings raise questions on how to interpret and communicate the detection of fentanyl and related opioids in other drugs. We present three potential interpretations: (1) mistaken and misrepresented samples where the expected drug was never detected, (2) cross contamination when opioids were at trace concentration levels, or (3) adulteration as the least frequent scenario where opioids were detected above trace concentrations in combination with the expected drug.

conclusionsIn a region where fentanyl is associated with extreme rates of overdose, it remains rare to find such opioids in other drugs. However, the risk of fentanyl in other drugs remains an ongoing threat that warrants responses by individuals and public health. We provide possible interpretations to inform such responses. Our data raises questions on how to interpret and communicate the detection of fentanyl and other opioids in other drugs.

Indexed as

Analgesics, OpioidFentanylIllicit DrugsSubstance Abuse DetectionBritish ColumbiaDrug ContaminationHumansMass SpectrometryAnalgesics, OpioidFentanylIllicit DrugsDrug checkingFentanylHarm reductionOverdose

Identifiers

PMID40065423
PMCPMC11892297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.